Joseph M. Grimm
Plus aucun poste en cours
Profil
Mr. Joseph M.
Grimm is Chief Financial Officer at Prospect Therapeutics, Inc. and Chief Financial Officer & Vice President-Finance at Alpha-Beta Technology, Inc.
Mr. Grimm was previously employed as Chief Financial Officer by Modular Genetics, Inc., Chief Financial Officer by NetMed, Inc., Chief Financial Officer by NitroMed, Inc., and Treasurer & Vice President-Finance by Genetics Institute LLC.
He received his undergraduate degree from the University of Wisconsin and an MBA from the University of Minnesota.
Anciens postes connus de Joseph M. Grimm
| Sociétés | Poste | Fin |
|---|---|---|
Modular Genetics, Inc.
 Modular Genetics, Inc. BiotechnologyHealth Technology Modular Genetics, Inc. designs and develops engineered microorganisms that synthesize chemicals. Its proprietary advanced technology in synthetic biology to produce products that are cost competitive, provide superior performance and are environmentally friendly. The firm’s technology can be used in various areas that include bioplastics, semisynthetic drugs, biodiesel, biosurfactants, and commodity chemical feedstocks. The company was founded by Kevin A. Jarrell and Temple F. Smith in 2000 and is headquartered in Woburn, MA. | Directeur Financier/CFO | - |
Alpha-Beta Technology, Inc.
 Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Directeur Financier/CFO | - |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Directeur Financier/CFO | - |
Prospect Therapeutics, Inc.
 Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Directeur Financier/CFO | - |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Directeur Financier/CFO | - |
Formation de Joseph M. Grimm
| University of Wisconsin | Undergraduate Degree |
| University of Minnesota | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NETMED, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Alpha-Beta Technology, Inc.
Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
Modular Genetics, Inc.
Modular Genetics, Inc. BiotechnologyHealth Technology Modular Genetics, Inc. designs and develops engineered microorganisms that synthesize chemicals. Its proprietary advanced technology in synthetic biology to produce products that are cost competitive, provide superior performance and are environmentally friendly. The firm’s technology can be used in various areas that include bioplastics, semisynthetic drugs, biodiesel, biosurfactants, and commodity chemical feedstocks. The company was founded by Kevin A. Jarrell and Temple F. Smith in 2000 and is headquartered in Woburn, MA. | Health Technology |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
